

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

RESIGNATION OF EXECUTIVE DIRECTOR AND AUTHORISED REPRESENTATIVE

The Board of the Company hereby announces that Ms. Lee Nga Yan has resigned as an executive director of the Company and one of the authorised representatives of the Company as required under Rule 3.05 of the Listing Rules and the authorised representative of the Company for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance with effect from 29 December 2015 due to her other business commitments requiring more dedication and time.

This announcement is made by Innovative Pharmaceutical Biotech Limited (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

RESIGNATION OF EXECUTIVE DIRECTOR AND AUTHORISED REPRESENTATIVE

The board of directors (the “**Board**”) of the Company hereby announces that Ms. Lee Nga Yan (“**Ms. Lee**”) has resigned as an executive director of the Company and one of the authorised representatives of the Company as required under Rule 3.05 of the Listing Rules and the authorised representative of the Company for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance (Chapter 622 of the laws of Hong Kong) (the “**Companies Ordinance**”) with effect from 29 December 2015 due to her other business commitments requiring more dedication and time.

Ms. Lee has confirmed to the Company that there is no disagreement with the Company in any respect and save as otherwise disclosed herein, there are no matters which need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) in relation to her resignation.

The Board would also like to take this opportunity to express its gratitude to Ms. Lee for her contribution to the Company during her term of service.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Jiang Nian
Chairman

Hong Kong, 29 December 2015

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive director of the Company), Mr. Tang Rong (executive director of the Company), Ms. Xiao Yan (non-executive director of the Company), Ms. Wu Yanmin (non-executive director of the Company), Ms. Chen Weijun (independent non-executive director of the Company), Dr. Zhang Zhihong (independent non-executive director of the Company) and Mr. Wang Rongliang (independent non-executive director of the Company).